Lifevantage (LFVN) Expected to Post Quarterly Earnings on Thursday

Lifevantage (NASDAQ:LFVN) is expected to announce its Q4 2026 results after the market closes on Thursday, August 27th. Analysts expect Lifevantage to post earnings of $0.15 per share and revenue of $44.00 million for the quarter. Parties may review the information on the company’s upcoming Q4 2026 earning overview page for the latest details on the call scheduled for Thursday, August 27, 2026 at 4:30 PM ET.

Lifevantage Price Performance

LFVN opened at $6.84 on Wednesday. The stock has a market cap of $86.29 million, a price-to-earnings ratio of 15.20 and a beta of 0.72. Lifevantage has a twelve month low of $3.90 and a twelve month high of $14.28. The company’s 50-day moving average price is $6.41 and its two-hundred day moving average price is $5.81.

Lifevantage Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 15th. Stockholders of record on Tuesday, September 1st will be paid a dividend of $0.05 per share. The ex-dividend date is Tuesday, September 1st. This represents a $0.20 annualized dividend and a dividend yield of 2.9%. Lifevantage’s dividend payout ratio (DPR) is presently 44.44%.

Institutional Trading of Lifevantage

Several hedge funds and other institutional investors have recently modified their holdings of the business. Jane Street Group LLC boosted its holdings in shares of Lifevantage by 5.4% in the first quarter. Jane Street Group LLC now owns 36,567 shares of the company’s stock worth $533,000 after acquiring an additional 1,877 shares during the period. Cetera Investment Advisers grew its position in shares of Lifevantage by 10.8% in the second quarter. Cetera Investment Advisers now owns 20,098 shares of the company’s stock valued at $263,000 after purchasing an additional 1,954 shares in the last quarter. Invesco Ltd. raised its stake in shares of Lifevantage by 13.6% during the 4th quarter. Invesco Ltd. now owns 30,085 shares of the company’s stock valued at $185,000 after purchasing an additional 3,603 shares during the period. JPMorgan Chase & Co. raised its stake in shares of Lifevantage by 870.2% during the 2nd quarter. JPMorgan Chase & Co. now owns 5,016 shares of the company’s stock valued at $66,000 after purchasing an additional 4,499 shares during the period. Finally, LPL Financial LLC lifted its holdings in Lifevantage by 19.0% during the 4th quarter. LPL Financial LLC now owns 28,303 shares of the company’s stock worth $174,000 after purchasing an additional 4,524 shares in the last quarter. Institutional investors own 35.32% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently commented on the company. Lake Street Capital downgraded Lifevantage from a “buy” rating to a “hold” rating and set a $5.00 price objective on the stock. in a research note on Thursday, May 7th. Weiss Ratings reissued a “hold (c)” rating on shares of Lifevantage in a research report on Friday. Two research analysts have rated the stock with a Hold rating, According to MarketBeat, Lifevantage presently has a consensus rating of “Hold” and an average target price of $5.00.

About Lifevantage

LifeVantage Corporation is a publicly traded company that develops, markets and distributes nutritional supplements, skincare products and weight-management solutions through a direct-selling business model. The company’s flagship offering, Protandim®, is formulated to activate the Nrf2 pathway, which is associated with cellular defense processes. LifeVantage also markets the PhysIQ® line for metabolism and body composition support and the TrueScience® skincare regimen, targeting a range of health and wellness needs.

Founded in 1999 and headquartered in Sandy, Utah, LifeVantage combines research in nutrigenomics with a network of independent distributors to bring its products to market.